Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2023-04-05 Earnings Release
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'GeNeuro annonce ses résultats annuels 2022'. It provides a summary of financial results, operational highlights, and business developments for the fiscal year 2022. While it contains financial tables, it is structured as a press release (Communiqué de presse) rather than a full 10-K or formal annual report document. In the context of financial reporting, this type of initial announcement of annual results is classified as an Earnings Release (ER). FY 2022
2023-04-05 French
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a new EUR 25 million credit facility agreement between GeNeuro and the European Investment Bank (EIB). It details the terms of the loan, the tranches, interest rates, and the associated warrant agreement. This falls under the category of company financing and capital structure updates, which is best classified as a Capital/Financing Update (CAP).
2023-03-07 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a new credit agreement (financing) between GeNeuro and the European Investment Bank (EIB). It details the terms of the loan, including tranches, interest rates, and the issuance of warrants (BSA) which could lead to share dilution. This falls squarely under the definition of a Capital/Financing Update (CAP), as it describes a specific fundraising/financing activity.
2023-03-07 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Regulatory Filings Classification · 1% confidence The document is a monthly statement of total voting rights and shares, which is a standard regulatory disclosure required by the AMF (French Financial Markets Authority) under Article 223-16. While it mentions voting rights, it is not a report of a specific shareholder vote result (DVA), but rather a periodic disclosure of capital structure and voting rights. Since it does not fit into the specific categories of shareholder meeting results or major shareholding notifications, it falls under the general regulatory filing category.
2023-01-03 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure required by Article 223-16 of the AMF General Regulation, which mandates that listed companies provide monthly updates on the total number of shares and voting rights. This type of filing is a standard regulatory requirement for transparency regarding capital structure and does not fit into specific categories like 'Share Issue' (which would be a specific event) or 'Annual Report'. Therefore, it is classified as a Regulatory Filing (RNS).
2023-01-03 French
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version agrégée)
Transaction in Own Shares Classification · 1% confidence The document is a formal declaration of share buyback transactions ('Déclaration des transactions sur actions propres') conducted by the issuer GeNeuro. It provides a table of aggregated daily transactions and a detailed list of individual trades, including dates, volumes, prices, and the purpose of the repurchase (employee stock allocation). This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2020-11-19 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.